Cover Image
市場調查報告書

女性用避孕器:開發中產品分析

Female Contraception - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363113
出版日期 內容資訊 英文 73 Pages
訂單完成後即時交付
價格
Back to Top
女性用避孕器:開發中產品分析 Female Contraception - Pipeline Review, H1 2016
出版日期: 2016年06月15日 內容資訊: 英文 73 Pages
簡介

本報告提供女性用避孕器的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

女性用避孕器概要

女性用避孕器的開發

  • 開發中產品的概要
  • 開發中產品比較分析

女性用避孕器:企業開發中的治療藥

女性用避孕器:大學/機關研究中的治療藥

女性用避孕器:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

女性用避孕器:企業開發中的產品

女性用避孕器:大學/機關研究中的產品

女性用避孕器治療藥的開發企業

  • Agile Therapeutics, Inc.
  • ANI Pharmaceuticals, Inc.
  • Evofem, Inc.
  • Mithra Pharmaceuticals S.A.
  • Orbis Biosciences, Inc.

女性用避孕器:評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

簡介

女性用避孕器:暫停中的計劃

女性用避孕器:中止開發的產品

女性用避孕器:產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8180IDB

Summary

Global Markets Direct's, 'Female Contraception - Pipeline Review, H1 2016', provides an overview of the Female Contraception pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Female Contraception, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Female Contraception
  • The report reviews pipeline therapeutics for Female Contraception by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Female Contraception therapeutics and enlists all their major and minor projects
  • The report assesses Female Contraception therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Female Contraception

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Female Contraception
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Female Contraception pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Female Contraception Overview
  • Therapeutics Development
    • Pipeline Products for Female Contraception - Overview
    • Pipeline Products for Female Contraception - Comparative Analysis
  • Female Contraception - Therapeutics under Development by Companies
  • Female Contraception - Therapeutics under Investigation by Universities/Institutes
  • Female Contraception - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Female Contraception - Products under Development by Companies
  • Female Contraception - Products under Investigation by Universities/Institutes
  • Female Contraception - Companies Involved in Therapeutics Development
    • Agile Therapeutics, Inc.
    • ANI Pharmaceuticals, Inc.
    • Evofem, Inc.
    • Mithra Pharmaceuticals S.A.
    • Orbis Biosciences, Inc.
  • Female Contraception - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (drospirenone + estetrol) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (estradiol acetate + nestorone) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (estradiol acetate + prasterone + progesterone) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AG-200 ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AG-200 SP - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AG-20015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Amphora - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etonogestrel ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EVE-106 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levonorgestrel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LJ-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates for Contraception - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOV-1003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-003296 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-0101255 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 1 for Fertility Control - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 2 for Fertility Control - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Modulate Progesterone Receptor for Fertility Control - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Contraception - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Female Contraception - Dormant Projects
  • Female Contraception - Discontinued Products
  • Female Contraception - Product Development Milestones
    • Featured News & Press Releases
      • Apr 05, 2016: FDA Feedback On Spa Estelle: A New Step Closer To The Launch Of Estelle Phase III Pivotal Clinical Studies
      • Apr 01, 2016: Topline Results Of Food Effect Study Of The Product Candidate Estelle, The New Combined Oral Contraceptive Composed Of 15 mg Of Estetrol (E4) And 3 mg Of Drospirenone
      • Mar 24, 2016: Already 4 European Countries Fully Approved Protocol Of MIT-ES001-C301 Estelle Phase III Clinical Study
      • Oct 19, 2015: Agile Therapeutics Announces Completion of Patient Enrollment in Twirla Phase 3 SECURE Clinical Trial
      • Oct 19, 2015: Agile Therapeutics Announces Completion of Patient Enrollment in Twirla Phase 3 SECURE Clinical Trial
      • Sep 22, 2015: Evofem Announces FDA Acceptance of New Drug Application for Amphora as a Contraceptive
      • Aug 31, 2015: Agile Therapeutics Announces Completion of Patient Recruitment in Twirla Phase 3 SECURE Clinical Trial
      • Aug 26, 2015: The European Journal Of Contraception And Reproductive Health Care Publishes Two Scientific Articles About E4 (Estetrol) Dinox Phase II Study: Two Of The Most Read Papers By The Scientific Community
      • Jul 13, 2015: Aquila Solutions,Partners with Evofem to Submit New Drug Application to U.S. FDA for Amphora as a Contraceptive
      • Jul 06, 2015: Evofem Submits New Drug Application to U.S. FDA for Amphora as a Contraceptive
      • Jan 13, 2015: Evofem Announces Pre-NDA Meeting With FDA for Amphora
      • Dec 01, 2014: Agile Therapeutics Announces Publication of Data on Low-Dose Investigational Contraceptive Patch
      • Sep 29, 2014: Agile Announces Dosing of First Patients in Twirla Phase 3 SECURE Study
      • Sep 16, 2014: Agile Initiates Phase 3 SECURE Study for Twirla
      • Jul 17, 2014: Agile Therapeutics Announces Allowance of Additional Patent Claims for Skinfusion
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Female Contraception, H1 2016
  • Number of Products under Development for Female Contraception - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Female Contraception - Pipeline by Agile Therapeutics, Inc., H1 2016
  • Female Contraception - Pipeline by ANI Pharmaceuticals, Inc., H1 2016
  • Female Contraception - Pipeline by Evofem, Inc., H1 2016
  • Female Contraception - Pipeline by Mithra Pharmaceuticals S.A., H1 2016
  • Female Contraception - Pipeline by Orbis Biosciences, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Female Contraception - Dormant Projects, H1 2016
  • Female Contraception - Dormant Projects (Contd..1), H1 2016
  • Female Contraception - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Female Contraception, H1 2016
  • Number of Products under Development for Female Contraception - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top